The usual recommended dose of Trepilizumab Injection is 3 mg/kg administered intravenously usually once every 2 weeks until disease progression or intolerable toxicity occurs. Trepilizumab is usually indicated for metastatic or unresectable melanoma that has failed prior systemic systemic therapy. Treatment of patients with recurrent/metastatic nasopharyngeal cancer who have failed prior second-line or higher systemic therapy. This product is not suitable for children under 18 years of age and the elderly, and should also be used with caution in patients with severe liver damage, while it can be used appropriately under the supervision of a doctor in patients with mild kidney damage. Adverse reactions such as rash, fever, malaise, decreased appetite, constipation, nausea, hypothyroidism or hyperthyroidism, anemia may occur with the use of this drug. Specific use of the drug should consult a doctor, should be under the guidance of a doctor with experience in oncology treatment, do not self-medication.